Clinical Trial Search

Primary: Objective Response Rate (RECIST Version 1.1) — 0; 0; 3; 8 Participants

Primary: Feasibility for Dose-dense TC Therapy: Number of Participants Receiving at Least 90% of Total Dose of Therapy — 37 participants

Primary: Number of Participants Experiencing Expected Toxicities — 13 Participants

Primary: Probability of Progression-free Survival (PFS) — 52 percentage probability

Primary: FEV1 AUC0-12 — 1.448; 1.416; 1.432; 1.416 Liter

Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 11; 12; 12; 11 Participants

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 85 — -8.91; -13.11; -8.63; -47.20 percent change — p=0.5661

Primary: Number of Participants With Adverse Events — 3; 9; 6; 1 Participants

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities — 0 Participants

Primary: Number of Participants With All Adverse Events (AE) and Serious Adverse Events (SAE) — 3; 4; 5; 6 Participants

Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies Greater Than or Equal to (≥) the Cut-off Value. — 312; 157; 279; 142 Participants

Primary: Number of Participants With Adverse Events — 1; 1; 2; 4 Participants

Primary: Autoinjector Assessment Period: Percentage of Successful Self-injections as Reported in the Questionnaires Completed by Both the Trial Site Personnel and the Patient…

Primary: Number of Subjects With Fever > 40.0°C (Rectal Temperature) — 0; 1 Participants

Primary: Pathologic Complete Response at the Time of Surgery — 10; 8; 0 Participants